Bavdegalutamide | ARV-110 | CAS#2222112-77-6 | PROTAC

MedKoo Cat#: 207155 | Name: Bavdegalutamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bavdegalutamide, also known as ARV-110, is a first-in-class PROTAC that effectively targets the wild type Androgen Receptor (AR) and certain genomic alterations of the AR (amplification, T878A, H875Y, F877L, M895V, but not L702H or AR-V7) for degradation in both enzalutamide sensitive and resistant preclinical models. ARV-110 showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC),

Chemical Structure

Bavdegalutamide

CAS#2222112-77-6

Theoretical Analysis

MedKoo Cat#: 207155

Name: Bavdegalutamide

CAS#: 2222112-77-6

Chemical Formula: C41H43ClFN9O6

Exact Mass: 811.3009

Molecular Weight: 812.30

Elemental Analysis: C, 60.62; H, 5.34; Cl, 4.36; F, 2.34; N, 15.52; O, 11.82

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
250mg	USD 1,450.00	2 Weeks
500mg	USD 2,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ARV-110; ARV 110; ARV110; Bavdegalutamide;

IUPAC/Chemical Name

N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide

InChi Key

CLCTZVRHDOAUGJ-SYVGMNBRSA-N

InChi Code

InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)/t26-,27-,34?

SMILES Code

ClC1=CC(O[C@H]2CC[C@@H](CC2)NC(C3=CC=C(N=N3)N4CCC(CC4)CN5CCN(CC5)C6=CC(C(N7C8CCC(NC8=O)=O)=O)=C(C=C6F)C7=O)=O)=CC=C1C#N

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Androgen receptor (AR) PROTAC degrader.

In vitro activity:

PROTAC-mediated AR degradation suppresses the expression of the AR-target genes PSA and FKBP5, inhibits AR-dependent cell proliferation, and induces potent apoptosis in VCaP cells. ARV-110 degrades clinically relevant mutant AR proteins and retains activity in a high androgen environment. In mouse xenograft studies, greater than 90% AR degradation is observed at a 1 mg/kg PO QD dose. Significant inhibition of tumor growth and AR signaling can be achieved in both an intact and castrate setting. Further, ARV-110 demonstrates in vivo efficacy and reduction of oncogenic Erg protein in a long term, castrate, enzalutamide-resistant VCaP tumor model. DMPK and exploratory toxicology studies show robust oral, dose proportional drug exposure in rodent and non-rodent species. Reference:Taavi Neklesa, et al. ARV-110: An androgen receptor PROTAC degrader for prostate cancer. American Association for Cancer Research. 2018. 78 (13): pp. 5236.

In vivo activity:

ARV-110 robustly degrades AR in all cell lines tested, with an observed halfmaximal degradation concentration (DC50) of ~1 nM. ARV-110 treatment leads to highly selective AR degradation, as demonstrated by proteomic studies. In VCaP cells, PROTAC-mediated AR degradation suppresses the expression of the AR-target gene PSA, inhibits AR-dependent cell proliferation, and induces apoptosis at low nanomolar concentrations. Further, ARV-110 degrades clinically relevant mutant AR proteins and retains activity in a high androgen environment. In mouse xenograft studies, greater than 90% AR degradation is observed at a 1 mg/kg PO QD dose. Significant inhibition of tumor growth and AR signaling has been achieved in LNCaP, VCaP and prostate cancer patient derived xenograft (PDX) models. Notably, ARV-110 demonstrates in vivo efficacy and reduction of AR-target gene expression in a long term, castrate, enzalutamide-resistant VCaP tumor model. Reference: Taavi K Neklesa,et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer. GU ASCO 2019

	Solvent	mg/mL	mM
Solubility
	DMSO	26.7	32.83

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 812.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Taavi Neklesa, et al. ARV-110: An androgen receptor PROTAC degrader for prostate cancer. American Association for Cancer Research. 2018. 78 (13): pp. 5236.

In vitro protocol:

Taavi Neklesa, et al. ARV-110: An androgen receptor PROTAC degrader for prostate cancer. American Association for Cancer Research. 2018. 78 (13): pp. 5236.

In vivo protocol:

Taavi K Neklesa,et al. ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer. GU ASCO 2019

1: Nguyen TT, Kim JW, Choi HI, Maeng HJ, Koo TS. Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies. Molecules. 2022 Mar 18;27(6):1977. doi: 10.3390/molecules27061977. PMID: 35335338; PMCID: PMC8954769. 2: Qi SM, Dong J, Xu ZY, Cheng XD, Zhang WD, Qin JJ. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Front Pharmacol. 2021 May 7;12:692574. doi: 10.3389/fphar.2021.692574. PMID: 34025443; PMCID: PMC8138175. 3: Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020 Feb;10(2):207-238. doi: 10.1016/j.apsb.2019.08.001. Epub 2019 Aug 13. PMID: 32082969; PMCID: PMC7016280. 4: Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem. 2021 Dec 5;225:113749. doi: 10.1016/j.ejmech.2021.113749. Epub 2021 Aug 10. PMID: 34411892. 5: Zeng S, Huang W, Zheng X, Liyan Cheng, Zhang Z, Wang J, Shen Z. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31. PMID: 33160761. 6: Xi JY, Zhang RY, Chen K, Yao L, Li MQ, Jiang R, Li XY, Fan L. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery. Bioorg Chem. 2022 Aug;125:105848. doi: 10.1016/j.bioorg.2022.105848. Epub 2022 May 5. PMID: 35533582. 7: Jimenez DG, Sebastiano MR, Caron G, Ermondi G. Are we ready to design oral PROTACs®? ADMET DMPK. 2021 Aug 31;9(4):243-254. doi: 10.5599/admet.1037. PMID: 35300370; PMCID: PMC8920102. 8: Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, Chen Y, Fan L, Ma H, Gong Y, Xie Y. An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed. 2022 Dec 20;3(1):46. doi: 10.1186/s43556-022-00112-0. PMID: 36536188; PMCID: PMC9763089. 9: Yedla P, Babalghith AO, Andra VV, Syed R. PROTACs in the Management of Prostate Cancer. Molecules. 2023 Apr 25;28(9):3698. doi: 10.3390/molecules28093698. PMID: 37175108; PMCID: PMC10179857. 10: Proof-of-Concept with PROTACs in Prostate Cancer. Cancer Discov. 2020 Aug;10(8):1084. doi: 10.1158/2159-8290.CD-NB2020-054. Epub 2020 Jun 5. PMID: 32503798. 11: Jia X, Han X. Targeting androgen receptor degradation with PROTACs from bench to bedside. Biomed Pharmacother. 2023 Feb;158:114112. doi: 10.1016/j.biopha.2022.114112. Epub 2022 Dec 9. PMID: 36508999. 12: Hemkens M, Stamp K, Loberg LI, Moreau K, Hart T. Industry perspective on the nonclinical safety assessment of heterobifunctional degraders. Drug Discov Today. 2023 May 26;28(8):103643. doi: 10.1016/j.drudis.2023.103643. Epub ahead of print. PMID: 37244567.